Related Experiment Video
Updated: Jan 9, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Dofetilide in atrial fibrillation: A comprehensive review
Diksha Mahendru1, Harin D Joshi2, Peter Kowey3
1Division of Internal Medicine, Lankenau Medical Center, Wynnewood, PA, USA.
None:
Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with significant morbidity, mortality, and healthcare burden worldwide. The management of AF remains complex, encompassing rate and rhythm control strategies, anticoagulation, and comorbidity optimization. Dofetilide, a class III antiarrhythmic agent, has emerged as an important therapeutic option for rhythm control due to its relatively selective blockade of the rapid component of the delayed rectifier potassium current (IKr). Unlike many other antiarrhythmics, it lacks significant negative inotropy, making it safe for use in patients with structural heart disease and left ventricular dysfunction. However, its use is limited by concerns regarding torsades de pointes, mandatory in-hospital initiation, and stringent monitoring requirements. This review provides a comprehensive analysis of dofetilide, including its pharmacology, clinical trial evidence, safety profile, guideline recommendations, role in special populations, real-world application in India, and future perspectives.
Related Concept Videos
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias VI: Management of Dysrhythmias
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias V: Evaluating Dysrhythmias
Dysrhythmias I: Introduction

